1. Home
  2. UCTT vs CRNX Comparison

UCTT vs CRNX Comparison

Compare UCTT & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UCTT

Ultra Clean Holdings Inc.

HOLD

Current Price

$118.82

Market Cap

4.1B

Sector

Technology

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.70

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCTT
CRNX
Founded
1991
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.9B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
UCTT
CRNX
Price
$118.82
$36.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$97.33
$76.75
AVG Volume (30 Days)
1.3M
1.0M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,734,500,000.00
$1,039,000.00
Revenue This Year
$19.18
$720.10
Revenue Next Year
$17.36
$184.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.28
$25.83
52 Week High
$125.00
$57.99

Technical Indicators

Market Signals
Indicator
UCTT
CRNX
Relative Strength Index (RSI) 61.83 52.34
Support Level $24.51 $33.14
Resistance Level N/A $44.89
Average True Range (ATR) 8.13 1.63
MACD 0.93 0.29
Stochastic Oscillator 80.94 68.55

Price Performance

Historical Comparison
UCTT
CRNX

About UCTT Ultra Clean Holdings Inc.

Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: